Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice
Highlights
► Nitazoxanide suppresses the production of IL-6 from LPS-stimulated macrophages. ► Nitazoxanide inhibits the LPS-induced expression of IL-6 mRNA in RAW 264.7 cells. ► Orally administered nitazoxanide suppresses the increase in IL-6 levels in the blood of thioglycollate-injected mice. ► Nitazoxanide could be a promising lead compound for agents against various diseases associated with overproduction of IL-6.
Introduction
Interleukin (IL)-6 is a multifunctional cytokine produced by a wide variety of cells, including fibroblasts, epithelial cells, macrophages, dendritic cells, mesangial cells, T cells, and B cells. IL-6 stimulates proliferation of hematopoietic progenitors, terminal differentiation of B cells into plasma cells, and activation and differentiation of T cells [1]. IL-6, together with IL-1β and tumor necrosis factor (TNF)-α, is also a proinflammatory cytokine that activates the hypothalamic-pituitary–adrenal axis and induces the hepatic acute phase response [2]. The biological activities of IL-6 integrate the innate and adaptive immune systems; therefore, IL-6 is involved in the host's defense response against pathogens.
Although IL-6 is pivotal in the development of immune responses, irregular production of IL-6 has been implicated in the development of various diseases. Abnormally high levels of IL-6 are detected in the serum of mice with inflammatory diseases, including multiple sclerosis [3], rheumatic arthritis [4], and host-versus-graft disease [5]. Constitutive expression of IL-6 in the liver of IL-6 transgenic mice causes glomerulonephritis [6]. Moreover, overproduction of IL-6 is strongly associated with the progression of neoplastic diseases such as Kaposi's sarcoma, multiple myeloma, renal carcinoma, plasmacytoma, and prostate cancer [7]. Therefore, inhibition of IL-6 production may be therapeutic in diseases characterized by IL-6 overproduction.
In response to lipopolysaccharide (LPS), the murine macrophage cell line RAW 264.7 readily secretes various pro-inflammatory mediators, including IL-6, IL-1β, TNF-α, nitric oxide, and prostaglandin E2 (PGE2). In this study, we used this cell line to find a potent inhibitor of IL-6 production. The levels of IL-6 in the culture supernatant of LPS-stimulated RAW 264.7 cells were determined by enzyme-linked immunosorbent assay (ELISA) in the presence of a compound. From our in-house stock compounds, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide (Fig. 1), inhibited the production of IL-6 in a concentration-dependent manner.
Nitazoxanide is a thiazolide compound that has long been used as an antiparasitic agent against protozoa, nematodes, and trematodes [8]. Nitazoxanide also has antimicrobial activity against some bacteria [9], [10] and viruses [11]. However, anti-inflammatory activities have never been reported for nitazoxanide. In this study, we report the first demonstration of the inhibitory activity of nitazoxanide on the production of IL-6 in vitro and in vivo.
Section snippets
Reagents
Nitazoxanide, LPS (Escherichia coli serotype O55; B5), Neutral Red, and thioglycollate broth (TG) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM) were obtained from Gibco (Grand Island, NY, USA). Nitazoxanide was dissolved as a 200 mM stock solution in dimethyl sulfoxide (DMSO). The final concentration of DMSO in culture media was less than 0.5%. For oral administration, nitazoxanide was dissolved in 1% DMSO in
The inhibitory activity of nitazoxanide on IL-6 production from RAW 264.7 cells stimulated with LPS
In the search for a compound with inhibitory activity against IL-6 production, we utilized a rapid screening system where IL-6 production from RAW 264.7 cells stimulated with LPS in the presence of each compound at a single concentration was determined by ELISA. From an in-house stock of 80 compounds, we found that nitazoxanide had such inhibitory activity. RAW 264.7 cells stimulated with LPS at a concentration of 1 μg/mL for 18 h produced an average of 1763.5 pg/mL of IL-6, which was
Discussion
Overproduction of IL-6 leads to various diseases, including inflammation, autoimmune disease, and even cancer. With a goal of developing a therapeutic agent for diseases associated with deregulated IL-6 production, we screened in-house stocks using a rapid screening system with LPS-stimulated RAW 264.7 cells. We found that nitazoxanide, a well-known antiparasitic agent, has inhibitory activity against IL-6 production in RAW 264.7 cells and peritoneal macrophages stimulated with LPS.
References (29)
- et al.
Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus–pituitary–adrenal axis by interleukin-1
Blood
(1996) - et al.
Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice
Blood
(1994) - et al.
Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides
Exp Parasitol
(2008) - et al.
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Immunity
(2011) - et al.
Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP
Blood
(2004) Interleukin-6: discovery of a pleiotropic cytokine
Arthritis Res Ther
(2006)- et al.
Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis
Eur J Immunol
(1990) - et al.
Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases
Scand J Rheumatol
(1988) - et al.
Increased IL-6 production and IL-6-mediated Ig secretion in murine host-vs-graft disease
J Immunol
(1993) - et al.
More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer
J Leukoc Biol
(2010)
Nitazoxanide: an important advance in anti-parasitic therapy
Am J Trop Med Hyg
In vitro and in vivo activities of nitazoxanide against Clostridium difficile
Antimicrob Agents Chemother
Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole
Antimicrob Agents Chemother
In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide
Vet Med Int
Cited by (52)
Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide
2023, Fish and Shellfish ImmunologyQuantitation of tizoxanide in multiple matrices to support cell culture, animal and human research
2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesA randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
2022, eClinicalMedicineCitation Excerpt :In the 25 years since nitazoxanide was first introduced, approximately 500 million people have been treated worldwide, and the drug has demonstrated a favorable safety record in both adults and children. Nitazoxanide has been previously shown to be active in vitro against a broad range of viruses including MERS and certain animal coronaviruses6–8 and suppress secretion of cytokines associated with the inflammatory response to respiratory infection.9,10 Recently, nitazoxanide was identified as a candidate drug for SARS-CoV-2 infection based on high throughput screening and in vitro virus culture.11–15
Interferon-inducer antivirals: Potential candidates to combat COVID-19
2021, International ImmunopharmacologyCitation Excerpt :Given the presence of mTOR catalytic subunit in both mTORC1 and mTORC2, it could possibly block the kinase activity of mTOR indirectly, and might probably affect the upstream mTORC1 regulatory pathway [103]. One study showed that it exerted inhibitory activity against IL-6 production from murine macrophages both in vitro and in vivo [104]. NTZ also enhanced the IRF3-induced IFNβ reporter activity in a dose-dependent way, and in the RIG-I overexpressing cells triggered with 1AB.
Comparing the effect of nitazoxanide and tylosin against necrotic enteritis in broilers
2024, Journal of Advanced Veterinary Research